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Abstract
Notch signaling between neighboring cells controls many cell fate decisions in metazoans both during embryogenesis and
in postnatal life. Previously, we uncovered a critical role for physiological Notch signaling in suppressing osteoblast
differentiation in vivo. However, the contribution of individual Notch receptors and the downstream signaling mechanism
have not been elucidated. Here we report that removal of Notch2, but not Notch1, from the embryonic limb mesenchyme
markedly increased trabecular bone mass in adolescent mice. Deletion of the transcription factor RBPjk, a mediator of all
canonical Notch signaling, in the mesenchymal progenitors but not the more mature osteoblast-lineage cells, caused a
dramatic high-bone-mass phenotype characterized by increased osteoblast numbers, diminished bone marrow
mesenchymal progenitor pool, and rapid age-dependent bone loss. Moreover, mice deficient in Hey1 and HeyL, two
target genes of Notch-RBPjk signaling, exhibited high bone mass. Interestingly, Hey1 bound to and suppressed the NFATc1
promoter, and RBPjk deletion increased NFATc1 expression in bone. Finally, pharmacological inhibition of NFAT alleviated
the high-bone-mass phenotype caused by RBPjk deletion. Thus, Notch-RBPjk signaling functions in part through Hey1-
mediated inhibition of NFATc1 to suppress osteoblastogenesis, contributing to bone homeostasis in vivo.
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Introduction
Notch signaling mediates communication between neighboring
cells to control cell fate decisions in all metazoans [1,2]. The
mammalian genome encodes four Notch receptors (Notch1-4) and
at least five ligands (Jagged1, 2 and Delta-like 1, 3, 4) [3]. In the
canonical Notch pathway, binding of the ligands to the Notch
receptors present on the neighboring cell surface triggers two
successive intramembrane proteolytic cleavages of the receptors
mediated by the c-secretase complex and resulting in the release of
the Notch intracellular domain (NICD) [4,5,6]. Upon its release
from the plasma membrane, NICD translocates to the nucleus
where it interacts with a transcription factor of the CSL family
(RBPjk/CBF-1 in mammals) to activate transcription of target
genes [7]. Among the best known targets of Notch/RBPjk
signaling are the Hes/Hey family of basic helix-loop-helix (bHLH)
transcription repressors [8]. However, the regulation of individual
Hes/Hey proteins by Notch and their role in mediating Notch
function are highly dependent on cell context. In addition to the
canonical pathway, Notch has also been reported to signal through
noncanonical, RBPjk-independent mechanisms, but the molecular
nature of these mechanisms is not well understood [6,9,10,11].
Notch signaling has emerged as a critical regulator of the
mammalian skeleton. Initial mouse genetic studies identified a role
for Notch in axial skeletal patterning, as mice lacking either Delta-
like 3 (Dll3) [12], presenilin 1 (PS1) [13,14], a catalytic subunit of
the c-secretase complex, or lunatic fringe, a glycosyltransferase
that modifies Notch proteins [15], exhibited defects in the axial
skeleton due to deficiency in somite segmentation and mainte-
nance. In addition, mice lacking either Notch1 and 2 specifically in
the limb bud ectoderm or Jagged2 globally displayed syndactyly
[16,17]. Consistent with the mouse studies, human mutations in
Dll3 [18] were found to cause spondylocostal dysostosis, whereas
those in Notch2 [10] and Jagged1 [19,20] were responsible for
Alagille syndrome.
More recent mouse genetic studies have expanded our view of
Notch function in the osteoblast lineage. By genetically removing
both catalytic subunits of the c-secretase complex, PS1 and PS2,
or both Notch1 and 2 in the embryonic limb mesenchyme, we
have shown that Notch critically controls postnatal bone
homeostasis: the Notch-deficient long bones exhibited excessive
bone formation in adolescent mice with concomitant loss of bone
marrow mesenchymal progenitors [21]. Consistent with the
negative role of Notch in osteoblast differentiation, Zanotti et al
reported that forced-expression of NICD in osteoblastic precursors
reduced osteoblast numbers and caused osteopenia [22]. Con-
versely, forced-expression of NICD at a later stage of the osteoblast
lineage led to sclerosis owing to excessive proliferation of the
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constitutive Notch activation in the osteoblast lineage [23,24].
The negative role of physiological Notch signaling in osteoblast
differentiation uncovered in mice is congruent with the clinical
findings that Notch1 haploinsufficiency causes ectopic osteoblast
differentiation and calcification in the aortic valves [25,26],
whereas Notch2 stabilizing mutations are responsible for the
Hadju-Cheney syndrome, a disorder of severe and progressive
bone loss [27,28]. However, the signaling cascade through which
Notch inhibits osteoblastogenesis is not yet well understood.
Here we have genetically assessed the role of RBPjk and Hey
proteins, known components of the Notch canonical pathway, in
the regulation of osteoblastogenesis. Moreover, we have evaluated
the role of NFAT in the high-bone-mass phenotype caused by
RBPjk deficiency. The NFAT (nuclear factor of activated T cells)
family of transcription factors (NFATc1-c4) [29] have been shown
to play important roles in several skeletal cell types, including
chondrocytes [30], osteoclasts [31] and osteoblasts [32,33]. Our
results support a model wherein canonical Notch signaling
suppresses osteoblastogenesis in part through inhibition of
NFATc1 transcription, therefore integrating extracellular signals
with transcription factors that control osteoblast differentiation.
Results
Notch2 plays a dominant role in suppressing bone
formation
Previously, simultaneous removal of both Notch1 and 2 (PNN
mice) from the embryonic limb mesenchyme with Prx1-Cre,
which targets all of the early limb bud mesenchyme and a subset of
the craniofacial mesenchyme [34], caused high bone mass due to
increased osteoblast differentiation [21]. To discern the individual
contributions of Notch1 versus 2 in the osteogenic progenitors, we
employed the same Cre-loxP strategy to delete the two receptors
separately. Western analyses confirmed that Notch1 or Notch2
was efficiently deleted in the limb mesenchyme of Prx1-Cre;
Notch1
f/f (PN1) or Prx1-Cre; Notch2
f/f (PN2) mice, respectively
(Figure 1A). As expected from our previous study of the PNN
mice, PN1 and PN2 mice were viable without gross morphological
anomalies. However, X-ray radiography of the limb bones at eight
weeks of age revealed a marked increase in mineral content within
the trabecular region of the PN2 but not the PN1 mice, when
compared with their respective littermate controls (data not
shown). Three-dimensional reconstruction using micro computed
tomography (mCT) of the proximal tibial trabecular region
confirmed this finding (Figure 1B). In particular, PN2 mice
exhibited a 130% increase in trabecular bone volume owing to
increased trabeculae numbers and decreased trabeculae spacing
(Table 1). The PN2 phenotype was less dramatic than that of the
PNN mice [21] (Figure 1B), indicating that Notch 1 performed a
discernible role in the absence of Notch 2, even though deletion of
Notch 1 alone did not cause an effect. Similar to the PNN mice,
the high bone mass in PN2 mice was not due to decreased total
osteoclast activity, as serum CTX levels, which reflect the amount
of cleaved type I collagen by osteoclasts in the whole animal, did
not differ significantly from the controls (Figure 1C). In addition,
osteoclast number or osteoclast surface per bone perimeter did not
change in either PN1 or PN2 mice (Figure 1D–1E). Therefore,
physiological signaling from Notch 2, rather than Notch 1, plays a
dominant role in suppressing bone formation.
RBPjk mediates Notch function in suppressing osteoblast
differentiation
To test the hypothesis that Notch suppresses bone formation
through the canonical pathway, we deleted RBPjk with Prx1-Cre
from the embryonic limb mesenchyme. Western analyses
confirmed that RBPjk was efficiently deleted in the tibia of the
Prx1-Cre; RBPjk
f/f (PRBP) mouse (Figure 2A). Moreover, Hey1
and HeyL, two Notch target genes previously identified in the
PNN bones [21], were markedly reduced in the PRBP tibia
(Figure 2B). The PRBP mice were born at mendelian ratio with no
gross abnormalities. However, at eight weeks of age, X-ray
radiography revealed that the PRBP mice contained much greater
mineral content within the presumptive bone marrow cavity than
the wild-type littermates (Figure 2C). mCT analysis of the proximal
tibia confirmed a marked increase of bone mass in the PRBP mice
(Figure 2C), as reflected in a 730%, 220% or 140% increase in
BV/TV, trabeculae number or trabeculae thickness, respectively,
coupled with a 70% decrease in trabeculae spacing (Table 2).
Consistent with the mCT data, both H&E and picrosirius red
staining of the tibia detected excessive trabecular bone occluding
much of the marrow cavity of the PRBP bones (Figure 2D, 2E).
These analyses also revealed an abnormal elongation of the
growth plate hypertrophic cartilage in the PRBP bones
(Figure 2D–2E); this phenotype was similar to that previously
analyzed in the PNN mice and could not be contributed to
changes in osteoclast numbers at the chondro-osseous junction
(Figure 3A, 3B). The dramatic increase in bone mass in the PRBP
mice was very similar to that seen in the presenilin 1- and 2-
deficient (PPS) animals, but more severe than the PNN phenotype,
likely due to contributions from Notch3 and 4 in the PNN mice
[21]. Although the data do not exclude that RBPjk may control
bone formation through a yet unknown mechanism independent
of Notch, the striking similarity in the bone phenotype among the
PPS, the PNN and the PRBP mice indicates that RBPjk is likely
the principle mediator of physiological Notch signaling in bone.
We then analyzed the cellular basis for the high bone mass in
the eight-week-old PRBP mice. Tartrate-resistant acid phospha-
tase (TRAP) staining on tibial sections revealed a strikingly uneven
distribution of osteoclasts within the trabecular bone region of the
PRBP mice: whereas TRAP-positive cells were more abundant
than normal within the metaphyseal region, few were detected
towards the diaphysis (Figure 3A). The reason for this regional
disparity is not certain at present but may be due to uneven
compartmentalization of osteoclast precursors within the occluded
marrow cavity. Serum CTX assay did not detect any significant
difference between the PRBP and the WT littermates (Figure 3C).
Further investigation of the metaphyseal region revealed that
although osteoclast number per bone perimeter (No. OC./mm)
was higher in the PRBP mice, the spreading of individual
osteoclasts (mm/OC.) was decreased, resulting in no change in the
Author Summary
Osteoporosis is a disease caused by disruption of the
balance between bone formation and resorption resulting
in a net loss of bone mass. Although anti-resorptive agents
are the current mainstay of osteoporosis therapy, novel
strategies to promote bone formation are critically needed
for more effective prevention and treatment of the
disease. Notch signaling, an evolutionally conserved
mechanism among multi-cellular organisms, was recently
shown to control bone formation and therefore represents
a potential target pathway for novel bone-promoting
therapeutics. In this study we elucidate the intracellular
signaling mechanism through which Notch controls bone
formation, providing a molecular framework that may
guide future drug development.
Notch and NFAT in Bone Formation
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(Figure 3D). Thus, the PRBP mice possessed abundant, but
apparently less functional osteoclasts within the metaphyseal
trabecular bone. Real-time PCR experiments showed that the
mRNA levels for both the osteoclastogenic signal Rankl and the
anti-osteoclastogenic factor Opg were reduced in the PRBP bone,
but the ratio of Rankl over Opg (Rankl/Opg) was 230% higher in
the PRBP bone than the control (Figure 3E). Moreover, the
mRNA level for M-CSF, a potent mitogen of osteoclast precursors,
was 690% higher in the PRBP mice (Figure 3F). The higher level
of M-CSF coupled with an increased ratio of Rankl/Opg could
explain the supernumerary but dysfunctional osteoclasts populat-
Figure 1. Bone phenotypes of PN1 and PN2 mice at 8 weeks of age. (A) Western blot analyses of Notch1 and 2 in PN1 and PN2 mice versus
wild-type (WT) littermates. Protein extracts prepared from limb buds of E12.5 PN1 embryos or tibiae and femora of 8-week-old PN2 mice. Numbers
indicate signal intensity relative to wild type (designated 1). N1-FL: full-length Notch 1; N1-TMIC, N2-TMIC: transmembrane-intracellular domaino f
Notch 1 and 2. Full-length N2 was not detected in either WT or PN2. (B) mCT three-dimensional reconstruction of metaphyseal trabecular bone of the
tibia. (C) Serum CTX assays. (D) Number of osteoclasts normalized to trabecular bone perimeter (#OC./B.S. (1/mm)) on tibial sections. (E) Osteoclast
surface normalized to bone surface (OC.S./B.S.) on tibial sections. Bar graphs show mean 6 s.d., n=3.
doi:10.1371/journal.pgen.1002577.g001
Table 1. mCT analyses of PN1 and PN2 at 8 weeks of age.
BV/TV Tb.N* Tb.Th* Tb.Sp*
Genotype % (±s.d.)
Ratio
over WT
p
value
1/mm
(±s.d.)
Ratio
over WT
p
value
mm
(±s.d.)
Ratio
over WT
p
value
mm
(±s.d.)
Ratio
over WT
p
value
PN1 13.08766.413 1.3 0.498 2.82760.295 1.2 0.137 0.06860.016 1.0 0.910 0.36860.043 0.8 0.168
WT 9.16364.320 2.33660.321 0.07060.006 0.44460.066
PN2 21.34362.788 2.3 0.004 3.47160.262 1.6 0.015 0.07260.017 1.2 0.568 0.29860.032 0.6 0.023
WT 9.10062.326 2.10660.510 0.08360.027 0.47460.078
BV: bone volume; TV; total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing; data derived from 100 of 16-mm slices
immediately below growth plate, n=3 for each group. All analyses were performed with sex-matched littermates (all males for PN1, 1 male and 2 females for PN2).
doi:10.1371/journal.pgen.1002577.t001
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the high bone mass in the PRBP mice was not caused by an overall
decrease in bone resorption.
Having ruled out resorption deficiency as the main cause for the
high bone mass in PRBP mice, we next focused on bone formation
parameters. Static histomorphometry of tibial sections from the
eight-week-old PRBP mice revealed a marked increase in the
number of cuboidal (active) osteoblasts, when normalized to either
bone perimeter (60% increase) or trabecular bone area (400%
increase) (Figure 4A). The number of flat (inactive) osteoblasts,
when normalized to trabecular bone area, was also increased by
100% in the PRBP mice. Consistent with the increase in osteoblast
number, real-time PCR experiments showed that a number of
common osteoblast markers were upregulated in bone total RNA
(Figure 4B). Dynamic histomorphometry showed that the mineral
apposition rate (MAR), which measured osteoblast activity, did not
Figure 2. Bone mass of PRBP mice at 8 weeks of age. (A) Western analysis for RBPjk in protein extracts from tibiae and femora. (B) Real-time
PCR with RNA from tibiae. (C) X-ray radiographs of hindlimbs (left), and mCT images of metaphyseal trabecular bone of the tibia (right). (D) H&E
staining of medial longitudinal sections through the tibia. (E) Picrosirus red staining on medial longitudinal sections through the tibia. CollagenI
stains red. Bar graphs show mean 6 s.d., *p,0.05, **p,0.01, n=3.
doi:10.1371/journal.pgen.1002577.g002
Table 2. Age-dependent bone loss in PRBP mice.
BV/TV Tb.N* Tb.Th* Tb.Sp*
Age Genotype % (±s.d.)
Ratio
over
WT
p
value
1/mm
(±s.d.)
Ratio
over
WT
p
value
mm
(±s.d.)
Ratio
over
WT
p
value
mm
(±s.d.)
Ratio
over
WT p value
8 weeks PRBP 47.217611.535 8.3 0.003 5.68360.980 3.2 0.002 0.137360.046 2.4 0.038 0.18060.027 0.3 0.000
WT 5.66060.986 1.78160.075 0.05760.001 0.57760.030
26 weeks PRBP 24.70064.740 1.5 0.181 4.55361.473 2.3 0.016 0.08060.011 1.0 0.930 0.24860.114 0.4 0.374
WT 16.27561.622 1.96560.333 0.07960.010 0.55260.095
BV: bone volume; TV; total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing; data derived from 100 of 16-mm slices
immediately below growth plate. All analyses were performed with sex-matched littermates (1 male and 2 females for 8 weeks, 2 males and 2 females for 26 weeks).
doi:10.1371/journal.pgen.1002577.t002
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(Figure 4C). However, the percentage of double-labeled trabcular
bone surface was increased by 230% in the PRBP mice, resulting
in a significant increase in the bone formation rate (BFR) within
the trabecular region (Figure 4C). Thus, the increase in bone mass
in the PRBP mice was primarily due to a marked increase in
osteoblast numbers.
To explore the mechanism responsible for the increase in
osteoblast numbers, we assessed the status of apoptosis and
proliferation of osteoblasts in PRBP versus wild-type bones. To
this end, osteoblast protein extracts were prepared from the bone
surface of the long bones, and subjected to Western analyses for
activated caspase 3 and PCNA, markers for apoptosis and cell
proliferation, respectively. These assays did not detect a significant
difference in either protein between the genotypes (Figure 4D).
Therefore, the increase in osteoblast numbers is unlikely to be
caused by changes in apoptosis or proliferation, but rather due to
enhanced differentiation from the progenitors.
RBPjk deletion causes diminution of bone marrow
mesenchymal progenitor pool and rapid age-dependent
bone loss
Uncontrolled osteoblast differentiation may lead to loss of bone
marrow mesenchymal progenitors and rapid age-dependent boss
loss [21]. To test whether this is the case in the PRBP mice, we
analyzed bone mass by X-ray (data not shown) and mCT at 26
weeks of age. Indeed, bone mass was drastically reduced in the
PRBP mice at 26 weeks when compared with 8 weeks (Figure 5A).
When quantified, the trabecular bone mass of the PRBP tibia was
no longer significantly different from the wild type at 26 weeks,
representing a drastic decline from a level 730% above normal at 8
weeks (Table 2). Similarly, both trabeculae thickness and number
were reduced to levels either equivalent or close to the wild type.
Interestingly, bone resorption, as measured by serum CTX assays,
was significantly higher in the PRBP mice over the control at 26
weeks, likely contributing to the rapid bone loss (Figure 5B).
Figure 3. Osteoclasts in PRBP mice at 8 weeks of age. (A) TRAP staining on medial longitudinal sections through the tibia. Osteoclasts stain red.
Color-coded boxed areas shown at higher magnification. (B) Osteoclast number normalized to cartilage perimeter at chondro-osseous junction (#
OC. / B.S. (1/mm)). (C) Serum CTX assays. (D) Left to right: osteoclast number normalized to trabecular bone perimeter (# OC. /B.S. (1/mm)), osteoclast
surface normalized to bone surface (OC. S. / B. S.), and average osteoclast surface (mm/OC.). (E–F) Real-time PCR with total RNA from tibiae. Bar graphs
show mean 6 s.d., *p,0.05, **p,0.01, n=3.
doi:10.1371/journal.pgen.1002577.g003
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high bone mass when young, rapidly lost bone with age.
We next assessed the status of the mesenchymal progenitors in
the bone marrow. To this end, bone marrow stromal cells (BMSC)
isolated from PRBP versus wild type littermates were subjected to
CFU-F (colony forming unit-fibroblast) assays. These assays were
not feasible with adolescent PRBP mice due to the occlusion of the
marrow cavity, and therefore performed only after six months of
age. Remarkably, no type I CFU-Fs could be detected from the
PRBP bone marrow at either 26 weeks (data not shown) or one
year (Figure 5C), indicating a severe diminution of the
mesenchymal progenitor pool. Moreover, BMSC isolated from
the PRBP bone were severely deficient in undergoing osteoblast
differentiation when cultured in osteogenic media and monitored
by the expression of alkaline phosphatase (AP) (Figure 5D).
Therefore, the PRBP animals exhibited a marked deficiency in the
bone marrow mesenchymal progenitor pool.
RBPjk is not critical for later stages of osteoblast lineage
To delineate potential stage-specific requirement of Notch-RBPjk
signaling during osteoblast differentiation, we deleted RBPjk with
either Osx-GFP::Cre [35] or 2.3ColI-Cre [36], which are believed to
target progressively more mature osteoblastic cells. Western analyses
confirmed that both Cre lines efficiently deleted RBPjk in the long
bones (Figure 6A). However, when assessed by either X-ray
radiography or mCT, neither deletion caused any significant changes
in bone mass at either 8 or 21 weeks of age (Figure 6B, 6C), a finding
confirmed by quantitative analyses (Table 3). Because previous studies
have suggested that Notch signaling in the more mature osteoblastic
cells regulated osteoclastogenesis through modulation of Rankl and
Opg [23,37], we examined osteoclasts in both the Osx-GFP::Cre;
RBPjk
f/f (OsxRBP) and the 2.3ColI-Cre; RBPjk
f/f (ColIRBP) mice.
However, serum CTX assays detected no significant changes in either
OsxRBP or ColIRBP mice over controls at either 8 or 21 weeks of age
(Figure 6D, 6E), indicating largely normal bone resorption in these
Figure 4. Osteoblasts in PRBP mice at 8 weeks of age. (A) Left to right: images of the trabecular bone region, osteoblast numbers normalized
to trabecular bone perimeter (#OB./mm) and area (#OB/mm
2) on sections. (B) Real-time PCR of bone total RNA. Osx: osterix; Bsp: bone sialoprotein;
Ocn: osteocalcin; Opn: osteopontin. (C) Left to right: images of calcein-double-labeled trabecular bone region; mineal apposite rate (MAR), double-
labeled surface over total bone surface (Dls/Tbs) and bone formation rate (BFR) in trabecular bone region. (D) Left to right: images of representative
Western blots with protein extracts from tibiae and femora; quantifications of Western analyses for PCNA and active caspase 3. Bar graphs show
mean 6 s. d., *p,0.05, n=3 (A–C) or 5 (D).
doi:10.1371/journal.pgen.1002577.g004
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surface were comparable between the mutant strains and their wild-
type littermates (Figure 6D, 6E). Thus, RBPjk does not appear to play
a major role in the more committed osteoblast-lineage cells.
Hey1 and HeyL mediate Notch-RBPjk signaling in
osteoblast lineage
To assess the role of Hey1 and HeyL in bone formation, we
analyzed the bones of mice wherein the two genes have been
deleted. Because previous work by others revealed no major bone
phenotype in the Hey1
2/2 mice [38], we focused on the HeyL
2/2
and the Hey1/HeyL double mutant animals, all in the C57BL6
background. As Hey1
2/2; HeyL
2/2 mice died prematurely due to
heart defects [39], we analyzed the bones of the viable HeyL
2/2;
Hey1
+/2 animals. mCT analyses showed that the HeyL
2/2 and the
HeyL
2/2; Hey1
+/2 mice possessed progressively more trabecular
bone than their wild-type littermates at 8 weeks of age (Figure 7A).
In particular, the femoral trabecular bone mass was increased by
80%and 150%overthe controlinthe HeyL
2/2 and the HeyL
2/2;
Hey1
+/2 animals, respectively (Table 4). Moreover, like the PRBP
bones, the HeyL
2/2;H e y 1
+/2 samples exhibited a significant
increase in trabeculae number and thickness with a corresponding
decrease in trabeculae spacing. At the cellular level, the HeyL
2/2;
Hey1
+/2 bones exhibited more cuboidal osteoblasts than the wild
type whereas their number of osteoclasts appeared to be normal
(Figure 7B, 7C). Thus, Hey1 and HeyL, like Notch and RBPjk,
negatively regulate osteoblast numbers.
NFATc1 functions downstream of Notch-RBPjk-Hey
signaling
We next investigated the mechanism through which Notch-
RBPjk-Hey signaling regulates osteoblast differentiation. In a
separate effort to identify Hey1 and HeyL target genes, we
performed genome-wide ChIP-seq (Chromatin immunoprecipita-
tion followed by high-throughput sequencing) experiments by
expressing Flag-tagged Hey1 or HeyL in HEK293 cells. We
identified strong binding for both proteins around the P1 promoter
of NFATc1 (Figure 8A and data not shown). Importantly, Hey1
was also found to bind to the NFATc1 P1 promoter region in ST2
cells, a mouse bone marrow stromal cell line that can be induced
to differentiate into osteoblasts (Figure 8B); the binding is
consistent with the presence of a predicted Hey1 binding site
‘‘CGCGCG’’ within the region. In contrast, no binding was
detected for the alternative P2 promoter (Figure 8B). We next
focused on the functional relevance of Hey1 binding. Full-length
Hey1, but not a form missing the HLH domain, suppressed the
activity of the NFATc1 P1 promoter in transient transfection
assays in both HEK293T and ST2 cells (Figure 8C). Because
NFATc1 was previously shown to increase osteoblast numbers
[33], we explored the potential involvement of NFATc1 in Notch-
RBPjk signaling in bone. Real-time PCR revealed that NFATc1
mRNA was increased by 200% in the PRBP tibia over the control
(Figure 8D). Western analyses identified a 70 kD isoform of
NFATc1 greatly induced in the PRBP bones, whereas a 77 kD
form was less affected (Figure 8E). To gain insight on the induced
isoform, we employed semi-quantitative RT-PCR to identify the
specific NFATc1 mRNA variant(s) increased in the PRBP bones.
The NFATc1 mRNA variants are known to differ both at the 59
end containing either exon1 or 2, and at the 39 end that either
terminates with exon 9b, or contains exon 9a through exon 11. By
using primer pairs spanning exons 1 and 3, 2 and 3, 8 and 9b or 8
and 11, we observed a marked increase of exon 1 in the PRBP
samples, whereas exon 2 was unchanged (Figure 8F). Moreover,
exon 9b was enriched in PRBP over wild type, whereas exon 11
Figure 5. Bone loss in PRBP mice at 26 weeks of age. (A) mCT reconstruction of metaphyseal trabecular bone of tibia in wild type (WT) and
PRBP mice. (B) Serum CTX assays. (C) Bone marrow CFU-F assays. (D) Alkaline phosphatase (AP) assays of BMSC in osteogenic medium. Bar graphs
show mean 6 s. d., *p,0.05, n=3.
doi:10.1371/journal.pgen.1002577.g005
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shown). Thus, an NFATc1 mRNA variant transcribed from the P1
promoter and containing exons 1 and 9b was specifically induced
in the PRBP bones.
The finding above raises the possibility that the increase in
NFATc1 might contribute to the high bone mass in the PRBP
mice, and further that inhibition of NFATc1 activity may be able
to alleviate the phenotype. To test this hypothesis, we injected
littermate PRBP animals daily with either FK506, a potent
inhibitor of NFAT signaling, or vehicle, for one month starting at
one month of age. As expected, the vehicle treatment did not alter
the high bone mass phenotype of the PRBP animals. However,
FK506 markedly reduced bone mass in the PRBP mice, especially
in the femur (Figure 8G and 8H, Table 5). This reversal of the
high bone mass occurred in the face of decreased bone resorption
in the FK506-treated animals, as indicated by a significantly lower
serum CTX level (Figure 8I), presumably due to the known role of
NFAT in osteoclastogenesis [31]. The suppression of bone
resorption may explain the observation that FK506 did not
consistently correct the high bone mass in the tibia (data not
shown). However, in one case where the serum CTX level was less
affected by FK506, both the tibia and the femur were corrected
(Figure S1). As controls, the wild-type littermates were subjected to
the same inhibitor or vehicle treatment. Similar to a previous
report [32], the trabecular bone mass was reduced in the wild-type
animals by FK506, but the extent of reduction was modest
compared to that seen in the PRBP mice (Figure S2). Overall, the
results showed that NFAT inhibition could override the effect of
RBPjk deletion on bone mass. Furthermore, because Hey1 directly
inhibits NFATc1 expression, Notch-RBPjk-Hey signaling appears
to inhibit bone formation in part by down-regulating NFATc1.
Discussion
The present study establishes canonical Notch signaling as a
critical mechanism for maintaining bone homeostasis under
normal physiological conditions. In this capacity, Notch appears
to function as a gatekeeper to ensure that a proper number of
Figure 6. Deletion of RBPjk at later stages of osteoblast lineage. (A) Western analyses of RBPjk in protein extracts from tibiae and femora
from OsxRBP and ColIRBP versus wild type (WT) littermates at 8 weeks of age. (B–C) X-ray radiographs of hindlimbs, and mCT reconstruction of tibia
metaphyseal trabecular region at 8 and 21 weeks of age. (D–E) Osteoclast parameters of OsxRBP and ColIRBP at 8 and 21 weeks of age. Bar graphs
show mean 6 s. d., n=3.
doi:10.1371/journal.pgen.1002577.g006
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of Notch signaling from the Osx-positive stage onward did not
have an obvious effect, we propose that Notch mainly controls the
transition from Runx2- to Osx-positive cells. Mechanistically,
Notch signals through RBPjk to induce transcription of Hey1 and
HeyL, which in turn inhibit osteoblast differentiation by
suppressing both Runx2 activity [21] and NFATc1 expression
(this study) (Figure 8J).
The current study not only demonstrates the stage- and
receptor-specificity of Notch signaling during osteoblast differen-
tiation, but also sheds light on the intracellular mechanism
mediating Notch function. Although RBPjk was previously shown
to mediate the effect of NICD overexpression on both chondro-
genesis and preosteoblast proliferation [24,40], this study estab-
lishes for the first time the importance of RBPjk in physiological
Notch signaling within the osteoblast lineage. Moreover, the
present study uncovers a direct regulation of NFATc1 expression
by Notch signaling.
The relationship between Notch and NFAT signaling warrants
further investigation. The direct suppression of NFATc1 promoter
by Hey1, and the dominant effect of FK506 over RBPjk removal
support the model wherein NFAT functions downstream of and
opposite to Notch signaling in regulating bone formation.
However, we cannot rule out that FK506 may have NFAT-
Table 3. mCT analyses of OsxRBP and ColIRBP at 8 and 21 weeks of age.
BV/TV Tb.N* Tb.Th* Tb.Sp*
Age Genotype % (±s.d.)
Ratio
over
WT
p
value
1/mm
(±s.d.)
Ratio
over
WT
p
value
mm
(±s.d.)
Ratio
over
WT
p
value mm (±s.d.)
Ratio
over
WT p value
8 weeks OsxRBP 5.15062.401 0.7 0.492 2.71060.492 1.4 0.083 0.05260.004 1.0 0.936 0.37460.077 0.7 0.082
WT 7.04564.587 1.88760.377 0.05160.002 0.56160.116
21 weeks OsxRBP 7.51360.792 0.8 0.400 1.90460.804 1.2 0.464 0.06060.005 0.8 0.069 0.58260.211 0.8 0.262
WT 8.92362.480 1.53060.167 0.07360.007 0.70160.086
8 weeks ColIRBP 6.00361.908 1.2 0.724 2.23060.556 1.1 0.771 0.05660.008 1.1 0.406 0.45160.096 0.8 0.550
WT 5.18763.216 2.13560.865 0.05160.003 0.53260.194
21 weeks ColIRBP 8.02561.024 0.8 0.394 1.70060.063 1.0 0.693 0.06960.002 0.9 0.172 0.60960.024 1.0 0.706
WT 9.53360.794 1.63560.273 0.07660.006 0.63060.198
BV: bone volume; TV; total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing; data derived from 100 of 16-mm slices
immediately below growth plate. All analyses performed with sex-matched littermates (3 females for ColIRBP at either 8 or 21 weeks, 2 males and 2 females for OsxRBP
at 8 weeks, 1 male and 2 females for OsxRBP at 21 weeks).
doi:10.1371/journal.pgen.1002577.t003
Figure 7. Bone phenotypes of Hey1 and HeyL mutant mice at 8 weeks of age. (A) mCT 3-D reconstruction of metaphyseal trabecular bone of
the femur from WT, HeyL
2/2, and HeyL
2/2; Hey1
+/2. (B) Number of osteoblasts per trabecular bone area on sections (No. OB/mm
2). (C) Number of
osteoclasts normalized to trabecular bone perimeter (No. OC/mm). Bar graphs show mean 6 s. d., ** p,0.01, n=4.
doi:10.1371/journal.pgen.1002577.g007
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acted on other cell types to affect bone mass indirectly. Our
finding that Hey1 binds to and suppresses the NFATc1 promoter
is consistent with a recent report that Notch inhibited NFATc1
transcription in ST2 and primary osteoblasts [41]. However,
NFATc1 is unlikely to be the sole effector, as simultaneous
removal of NFATc1 and RBPjk with Prx1-Cre did not rescue the
high bone mass phenotype caused by RBPjk deletion (data not
shown). NFATc2 may play a redundant role as it was previously
shown to stimulate osteoblast differentiation [32]. Indeed, Western
blotting showed that several isoforms of NFATc2 were markedly
increased in the PRBP bones over the control (Figure S3). The
mechanism for this upregulation however, is currently unknown.
Future experiments with simultaneous deletion of NFATc1 and
Table 4. mCT analyses of HeyL
2/2; Hey1
+/2 and HeyL
2/2 at 8 weeks of age.
BV/TV Tb. N* Tb.Th* Tb.Sp*
Genotype % (±s.d.)
Ratio
over
WT
p
value
1/mm
(±s.d.)
Ratio
over
WT
p
value
mm
(±s.d.)
Ratio
over
WT
p
value
mm
(±s.d.)
Ratio
over
WT
p
value
HeyL2/2 17.02762.818 1.8 0.006 2.41060.321 1.1 0.653 0.10160.003 1.2 0.129 0.45660.074 0.9 0.728
HeyL2/2;
Hey1+/2
23.25464.123 2.5 0.000 3.29560.480 1.5 0.014 0.10760.009 1.3 0.027 0.34460.048 0.7 0.036
WT 9.32061.675 2.24760.477 0.08160.018 0.48360.109
BV: bone volume; TV; total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing. Data derived from 100 of 16-mm slices
immediately below growth plate, n=4 for each group (all females in C57BL6 background).
doi:10.1371/journal.pgen.1002577.t004
Figure 8. Relationship between Notch-RBPjk and NFAT in bone. (A) ChIP-seq data showing Flag-Hey1 binding at NFATc1 P1 promoter region
in HEK293T cells. (B) ChIP showing Flag-Hey1 bound to P1 but not P2 promoter of NFATc1 in ST2 cells. 1: input; 2: Flag antibody; 3: IgG; 4: water
control; 5: molecular weight ladder. (C) NFATc1 P1 promoter luciferase reporter assays in ST2 and HEK293T cells. 1: co-transfection with pCS2; 2: co-
transfection with pCS2-Hey1; 3: co-transfection with pCS2-Hey1-DHLH. (D) NFATc1 real-time PCR with total RNA from tibiae of 8-week-old mice. (E)
Western blot analysis of NFATc1 in protein extracts from tibiae and femora at 8 weeks. (F) Exon-specific RT-PCR of NFATc1 mRNA variants in bone
RNA from 8-week-old mice. W: wild type mice; M: PRBP mice; GDH: glyceraldehyde 3-phosphate dehydrogenase. (G) X-ray radiographs of femora
from PRBP mice treated with vehicle (Veh.) or FK506 (FK). (H) mCT 3-D reconstruction of the femur metaphyseal trabecular region. (I) Serum CTX
assays. (J) A model for Notch signaling in regulating osteoblast differentiation. Q: stimulation; H: negative regulation. Bar graphs show mean 6 s. d.,
*p ,0.05, ** p,0.01, n=3.
doi:10.1371/journal.pgen.1002577.g008
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mediate Notch function in bone.
Notch-RBPjk removal from the early limb mesenchyme led to a
severe deficit in type I CFU-F in the postnatal bone marrow. This
phenotype could reflect either a direct requirement of Notch
signaling in the CFU-F cells, or a secondary effect due to changes
in osteoblast differentiation. To distinguish these possibilities, we
performed lineage-tracing experiments with the Rosa26 reporter
mouse, and observed that the type I CFU-F cells were not targeted
by Prx1-Cre although some stromal cells in the same culture were
(data not shown). In addition, experiments with a transgenic
mouse (TNR) that reports Notch-RBPjk signaling [42] revealed
that some stromal cells but not the type I CFU-F cells exhibited
canonical Notch signaling in vitro (data not shown). Thus,
diminution of bone marrow mesenchymal progenitors, as reflected
by CFU-F assays in vitro, was likely to be secondary to changes in
osteoblast differentiation. In this scenario, assuming mesenchymal
progenitors normally exist in equilibrium with Runx2-positive
osteogenic precursors, we envision that unchecked differentiation
of the latter due to Notch deficiency may lead to exodus of cells
from the mesenchymal progenitor pool. Alternatively, the altered
bone marrow environment due to the excessive bone mass in
Notch-deficient mice may be unfavorable for either establishing or
maintaining a normal mesenchymal progenitor pool.
A mechanistic understanding of the dominance of Notch2 over
Notch1 awaits further studies. A similar dominance of Notch2 over
1 was observed during nephron formation in the mouse embryo
[43,44], whereas a dominance of Notch1 over 2 was reported in the
skin [45,46] as well as in osteoclasts [37]. The mechanism
underlying the differential roles among Notch paralogs is currently
unclear, but it could reflect differences in either expression levels or
ligand-binding affinities among the different receptors within a
given cell type. This model predicts that Notch2 is normally
preferably activated in the osteogenic progenitors. Alternatively,
Notch1 and2 may be similarly activated but Notch2-NICD is more
potent than Notch1-NICD in suppressing osteoblast differentiation.
However, Notch 1 deficiency was sufficient to cause ectopic
ossification in human aortic valves [25]. Thus, the relative
contribution of Notch1 versus 2 in suppressing the osteogenic
program appears to be context dependent.
The effect of Notch signaling in osteoblast-lineage cells on
osteoclast differentiation is likely to be complex. Although TRAP-
positive osteoclasts were more abundant than normal within the
metaphyseal trabecular region of the PRBP bones, the total bone
resorptionactivitywasrelativelynormalat8weeksofage.However,
by 26 weeks bone resorption was more robust in the PRBP mice
than the littermate control, and likely contributed to the rapid bone
loss seen at this age. The mechanism for the age-dependent bone
resorption phenotype is not understood at present, but likely
involvesadditional factorsbeyondNotch deficiencyintheosteoblast
lineage. In addition,unlike the PRBP mice, the PN1,PN2, OsxRBP
and ColIRBP mice did not display an obvious bone resorption
phenotype at either 8 or 21 weeks, even though certain changes in
M-CSF,Rankl and Opgwereobserved inthese animals (Figure S4).
The lack of bone resorption phenotype in the ColIRBP mice
appears to be at odds with the previous report that deletion of
presenilin 1 and 2 by 2.3Col1-Cre caused an increase in bone
resorption at six months, although not at three months of age [23].
Besides trivial explanations such as slight age differences or genetic
background variations between the two studies, the discrepancy
could indicate that the previously observed effect was independent
of RBPjk. In summary, the predominant function of physiologic
canonical Notch signaling in the osteoblast lineage is suppression of
osteoblastogenesis from the precursors. Thus, potential pharma-
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beneficial for bone formation.
Materials and Methods
Mouse strains
The N1
f/f [47], N2
f/f [48], RBPjk
f/f [49], 2.3ColI-Cre [36], Osx-
GFP::Cre [35], Prx1-Cre [34], Hey1
+/2 [50], HeyL
2/2 [39] and
NFATc1
f/f [51] mouse strains are as previously described. The
Animal Studies Committee at Washington University approved all
mouse procedures.
Analyses of mice
Radiographs of mouse skeleton were generated using a Faxitron
X-ray system (Faxitron X-ray Corp) with 20-second exposure
under 25 kV. Micro computed tomography (mCT 40, Scanco
Medical AG) was used for three-dimensional reconstruction, and
quantification of bone parameters (threshold set at 200). Serum
CTX assays were conducted with mice without feeding for 6 hours
with the RatLaps ELISA kit (Immunodiagnostic Systems Ltd.).
H&E, TRAP and picro-sirius red staining were performed on
paraffin sections, following decalcification for postnatal samples.
For dynamic histomorphometry of postnatal mice, calcein (Sigma)
was injected intraparitoneally at 7.5 mg/kg on days 7 and 2 prior
to sacrifice, and bones were sectioned in methyl-methacrylate.
Bioquant II was used for quantification in both static and dynamic
bone histomophometry. FK506 (Sigma) was dissolved in DMSO
and was injected subcutaneously into one-month-old mice at
0.30 mg/kg/day for one month before harvest.
Cell cultures, transfections, and analyses of protein and
RNA
The CFU-F and osteoblast differentiation assays were pre-
formed as previously described [21]. Only type I CFU-Fs were
scored in the present study.
Transient transfections were performed as follows. ST2 were
plated at 3610
4/well in a 24-well plate overnight, and transfected
with pCS2-Hey1, pCS2-Hey1-DHLHoremptypCS2vector(0.2 mg)
[21], pNFATc1-0.8P1 (0.1 mg) [52] and pRL-Renilla (0.01 mg,
Promega) for 8 h using Lipofectamine (1 ml/well). HEK293T cells
were plated at 4610
5/well in a 12-well plate overnight, transfected
with pCS2-Hey1, pCS2-Hey1-DHLH or empty pCS2 vector
(0.4 mg), pNFATc1-0.8P1 (0.2 mg) and pRL-Renilla (0.02 mg) using
Fugene (1.8 ml/well). The transfected ST2 or HEK293T cells were
harvested at 48 hours after the beginning of transfection and
subjected to dual luciferase activity assays (Promega).
Western analyses were performed with bone proteins extracted
with RIPA buffer from tibiae and femora that were cut into small
pieces after bone marrow cells were flushed out. The Notch 1
monoclonal antibody mN1A was as previously described [53], and
the Notch 2 antibody (C651.6DbHN) was from Developmental
Studies Hybridoma Bank at the University of Iowa. The antibody
against RBPjk was from Cosmobio (Japan).
Real time PCR was performed with SYBR-Green (Roche) in
ABI-7500 (Applied Biosystems) using cDNA reverse-transcribed
from bone total RNA, extracted with Trizol (Invitrogen) from
pulverized tibia and femur after removal of the bone marrow.
Sequence information for the real-time PCR primers is listed in
Table S1. The exon-specific primers for NFATc1 (Table S2) were
as previously described [54], but the exons were renumbered
according to the current NCBI nucleotide database. Semi-
quantitative RT-PCR for NFATc1 was performed at an annealing
temperature of 57uC for 40 cycles. GAPDH used as loading
control was amplified for 30 cycles.
ChIP experiment
ST2 cells were infected with lentivirus to express a doxycycline-
inducible Flag-Hey1 transgene. Flag-Hey1 expression was induced
with100 ng/mL Doxycycline (Sigma D9891) for 12 hours. Chro-
matinand proteincomplexes werecrosslinkedfor 10 minutes in1%
formaldehyde and flash frozen. The chromatin was sonicated to an
average size of 200–450 bp using a Sonics Vibracell sonicator
(model Vcx 500). Chromatin complexes were immunoprecipitated
using an anti-Flag antibody (Sigma F1804). Immunoprecipitated
DNA fragments were amplified by PCR using primers adjacent to a
predicted Hey1-binding site within the P1 promoter of the mouse
NFATc1 gene (59 - TCTCGGTCTCACTCTGACGCA - 39 and
59 - TTCCCTCTTGTACACCTTTGCCCA - 39), or primers
near the P2 promoter approximately 4 Kb downstream (59 -
TCCGGGTTTACATAAACAAGCGGC - 39 and 59 - ACTG-
CACACCACGCTGAACAGGAA - 39).
ChIP–seq experiment
HEK293 cells that express a doxycycline-regulated Flag-Hey1
or -HeyL transgene were used for ChIP-seq analysis. Cells were
induced with 50 ng/ml doxycycline for 48 hours to ensure a low-
level expression and Hey1- or HeyL-containing chromatin was
immunoprecipitated with a Flag antibody. Cells carrying the same
transgenes but grown without doxycycline were used as control.
Preparation of ChIP libraries, Illumina sequencing and data
analysis were performed as previously described [55].
Supporting Information
Figure S1 Correction of the high-bone-mass phenotype in the
tibia by FK506. (A) X-ray radiographs of the tibia. Note a notable
correction of the shape of the tibia. (B) Data from mCT analyses
and serum CTX assays of animals in (A).
(TIF)
Figure S2 Effect of FK506 on trabecular bone mass of wild type
mice. Shown are mCT 3-D reconstruction images of the
metaphyseal trabecular region of the tibia.
(TIF)
Figure S3 Western analyses of NFATc2 in protein extracts from
tibiae and femora of 8-week-old PRBP versus wild-type litter-
mates.
(TIF)
Figure S4 Real-time PCR of osteoclastogenic factors in bone
RNA from indicated mouse strains. Values are normalized to wild
type levels (designated 1). Bar graphs show mean 6 s. d., *p,0.05,
**p,0.01, n=3.
(TIF)
Table S1 Real-time PCR primers.
(DOCX)
Table S2 NFATc1 exon-specific PCR primers.
(DOCX)
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